New combo pill for high blood pressure enters first human tests

NCT ID NCT07421401

Not yet recruiting Disease control Sponsor: Boryung Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new combination pill (BR1015-A) containing two blood pressure medicines, Fimasartan and Indapamide, in 58 healthy adults. The goal is to see how the body absorbs and processes the drugs and to check for any safety issues. Participants will take the pill once on four separate occasions under fasting conditions. This study does not treat high blood pressure but gathers important information for future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fimasartan and Indapamide combination tablet
What this could lead to: If successful, this could lead to a new once-daily pill that helps control high blood pressure more conveniently.
What could go wrong: This is a very early (Phase 1) study in only 58 healthy people, not patients. It only checks how the drug is processed and basic safety; it cannot tell us if it actually works for hypertension.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESSENTIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESSENTIAL HYPERTENSION

More trials for these conditions

Other studies related to the condition(s) this trial covers.